Molecular Gastrointestinal, Liver, and Pancreatic Pathology

Cell and Tissue Based Molecular Pathology

Volumn , Issue , 2009, Pages 269-295

  Pai, Rish K ^a   Wilcox, Rebecca ^b   Hart, John ^a  

^a Department of Clinical Pathology ^*  (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80052973700     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-044306901-7.50028-6     Document Type: Chapter

References (120)

1. Burt R, Neklason DW Genetic testing for inherited colon cancer. Gastroenterology 2005, 128(6):1696-1716.
2. de la Chapelle A Genetic predisposition to colorectal cancer. Nat Rev Cancer 2004, 4(10):769-780.
3. Kaz AM, Brentnall TA Genetic testing for colon cancer. Nat Clin Pract Gastroenterol Hepatol 2006, 3(12):670-679.
4. Leggett B When is molecular genetic testing for colorectal cancer indicated?. J Gastroenterol Hepatol 2002, 17(4):389-393.
5. Barnetson RA, Tenesa A, Farrington SM, et al. Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N Engl J Med 2006, 354(26):2751-2763.
6. Burgart LJ Testing for defective DNA mismatch repair in colorectal carcinoma: A practical guide. Arch Pathol Lab Med 2005, 129(11):1385-1389.
7. Gryfe R, Kim H, Hsieh ET, et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 2000, 342(2):69-77.
8. Jass JR Pathology of hereditary nonpolyposis colorectal cancer. Ann NY Acad Sci 2000, 910:62-73. discussion 73-74.
9. Jass JR Role of the pathologist in the diagnosis of hereditary nonpolyposis colorectal cancer. Dis Markers 2004, 20(4-5):215-224.
10. Kim GP, Colangelo LH, Wieand HS, et al. Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: A National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J Clin Oncol 2007, 25(7):767-772.
11. Lagerstedt Robinson K, Liu T, Vandrocova J, et al. Lynch syndrome (hereditary nonpolyposis colorectal cancer) diagnostics. J Natl Cancer Inst 2007, 99(4):291-299.
12. Lynch HT, Lynch JF Lynch syndrome: History and current status. Dis Markers 2004, 20(4-5):181-198.
13. Pawlik TM, Raut CP, Rodriguez-Bigas MA, et al. Colorectal carcinogenesis: MSI-H versus MSI-L. Dis Markers 2004, 20(4-5):199-206.
14. Peltomaki P, Vasen H Mutations associated with HNPCC predisposition: Update of ICG-HNPCC/INSiGHT mutation database. Dis Markers 2004, 20(4-5):269-276.
15. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003, 349(3):247-257.
16. Soreide K, Janssen EA, Söiland H, et al. Microsatellite instability in colorectal cancer. Br J Surg 2006, 93(4):395-406.
17. Suraweera N, Duval A, Reperant M, et al. Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. Gastroenterology 2002, 123(6):1804-1811.
18. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004, 96(4):261-268.
19. Umar A, Risinger JI, Hawk ET, Barrett JC Testing guidelines for hereditary nonpolyposis colorectal cancer. Nat Rev Cancer 2004, 4(2):153-158.
20. Vasen HF, Hendriks Y, de Jong AE, et al. Identification of HNPCC by molecular analysis of colorectal and endometrial tumors. Dis Markers 2004, 20(4-5):207-213.
21. Galiatsatos P, Foulkes WD Familial adenomatous polyposis. Am J Gastroenterol 2006, 101(2):385-398.
22. Nieuwenhuis MH, Vasen HF Correlations between mutation site in APC and phenotype of familial adenomatous polyposis (FAP): A review of the literature. Crit Rev Oncol Hematol 2007, 61(2):153-161.
23. Rajagopalan H, Nowak MA, Vogelstein B, Lengauer C The significance of unstable chromosomes in colorectal cancer. Nat Rev Cancer 2003, 3(9):695-701.
24. Rozen P, Macrae F Familial adenomatous polyposis: The practical applications of clinical and molecular screening. Fam Cancer 2006, 5(3):227-235.
25. Schulmann K, Pox C, Schmiegel W The patient with multiple intestinal polyps. Best Pract Res Clin Gastroenterol 2007, 21(3):409-426.
26. Sieber OM, Lipton L, Crabtree M, et al. Multiple colorectal adenomas, classic adenomatous polyposis, and germline mutations in MYH. N Engl J Med 2003, 348(9):791-799.
27. Sieber OM, Segditsas S, Knudsen AL, et al. Disease severity and genetic pathways in attenuated familial adenomatous polyposis vary greatly but depend on the site of the germline mutation. Gut 2006, 55(10):1440-1448.
28. Venesio T, Molatore S, Cattaneo F, et al. High frequency of MYH gene mutations in a subset of patients with familial adenomatous polyposis. Gastroenterology 2004, 126(7):1681-1685.
29. Brosens LA, van Hattem A, Hylind LM, et al. Risk of colorectal cancer in juvenile polyposis. Gut 2007, 57(5):965-967.
30. Chow E, Macrae F A review of juvenile polyposis syndrome. J Gastroenterol Hepatol 2005, 20(11):1634-1640.
31. Giardiello FM, Trimbath JD Peutz-Jeghers syndrome and management recommendations. Clin Gastroenterol Hepatol 2006, 4(4):408-415.
32. McGarrity TJ, Amos C Peutz-Jeghers syndrome: Clinicopathology and molecular alterations. Cell Mol Life Sci 2006, 63(18):2135-2144.
33. Merg A, Howe JR Genetic conditions associated with intestinal juvenile polyps. Am J Med Genet C: Semin Med Genet 2004, 129(1):44-55.
34. Issa JP CpG-island methylator phenotype in cancer. Nat Rev Cancer 2004, 4(12):988-993.
35. Jass JR Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 2007, 50(1):113-130.
36. Ogino S, Meyerhardt JA, Kawasaki T, et al. CpG-island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma. Virchows Arch 2007, 450(5):529-537.
37. Ogino S, Kawasaki T, Kirkner GJ, et al. Evaluation of markers for CpG-island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. J Mol Diagn 2007, 9(3):305-314.
38. Van Rijnsoever M, Elsaleh H, Joseph D, et al. CpG-island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer. Clin Cancer Res 2003, 9(8):2898-2903.
39. Vogelstein B, Kinzler KW Cancer genes and the pathways they control. Nat Med 2004, 10(8):789-799.
40. Weisenberger DJ, Siegmund KD, Campan M, et al. CpG-island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 2006, 38(7):787-793.
41. Wong JJ, Hawkins NJ, Ward RL Colorectal cancer: A model for epigenetic tumorigenesis. Gut 2007, 56(1):140-148.
42. Chen R, Rabinovitch PS, Crispin DA, et al. DNA fingerprinting abnormalities can distinguish ulcerative colitis patients with dysplasia and cancer from those who are dysplasia/cancer free. Am J Pathol 2003, 162(2):665-672.
43. Chen R, Bronner MP, Crispin DA, et al. Characterization of genomic instability in ulcerative colitis neoplasia leads to discovery of putative tumor suppressor regions. Cancer Genet Cytogenet 2005, 162:99-106.
44. Greten FR, Eckmann L, Greten TF, et al. IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004, 118(3):285-296.
45. Itkowitz SH Molecular biology of dysplasia and cancer in inflammatory bowel disease. Gastroenterol Clin N Am 2006, 35:553-571.
46. Loftus EV Epidemiology and risk factors for colorectal dysplasia and cancer in ulcerative colitis. Gastroenterol Clin N Am 2006, 35:517-531.
47. Odze RD Pathology of dysplasia and cancer in inflammatory bowel disease. Gastroenterol Clin N Am 2006, 35:533-552.
48. O'Sullivan JN, Bronner MP, Brentnall TA, et al. Chromosomal instability in ulcerative colitis is related to telomere shortening. Nat Genet 2002, 32:280-284.
49. Risques R, Rabinovitch PS, Brentnall TA Cancer surveillance in inflammatory bowel disease: New molecular approaches. Curr Opin Gastroenterol 2006, 22(4):382-390.
50. Connolly EM, Gaffney E, Reynolds JV Gastrointestinal stromal tumours. Br J Surg 2003, 90(10):1178-1186.
51. Corless CL, Schroeder A, Griffith D, et al. PDGFRα mutations in gastrointestinal stromal tumors: Frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 2005, 23(23):5357-5364.
52. Corless CL, Fletcher JA, Heinrich MC Biology of gastrointestinal stromal tumors. J Clin Oncol 2004, 22(18):3813-3825.
53. Daum O, Grossmann P, Vanecek T, et al. Diagnostic morphological features of PDGFRα-mutated gastrointestinal stromal tumors: Molecular genetic and histologic analysis of 60 cases of gastric gastrointestinal stromal tumors. Ann Diagn Pathol 2007, 11(1):27-33.
54. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the ABL tyrosine kinase on the growth of BCR/ABL positive cells. Nat Med 1996, 2(5):561-566.
55. Emory TS, Sobin LH, Lukes L, et al. Prognosis of gastrointestinal smooth-muscle (stromal) tumors: Dependence on anatomic site. Am J Surg Pathol 1999, 23(1):82-87.
56. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Int J Surg Pathol 2002, 10(2):81-89.
57. Heinrich MC, Corless CL, Duensing A, et al. PDGFR-activating mutations in gastrointestinal stromal tumors. Science 2003, 299(5607):708-710.
58. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-Kit in human gastrointestinal stromal tumors. Science 1998, 279(5350):577-580.
59. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM Gastrointestinal pacemaker cell tumor (GIPACT): Gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998, 152(5):1259-1269.
60. La Vecchia C, Negri E, Franceschi S, Gentile A Family history and the risk of stomach and colorectal cancer. Cancer 1992, 70(1):50-55.
61. Martin JF, Bazin P, Feroldi J, Cabanne F Intramural myoid tumors of the stomach: Microscopic considerations on 6 cases. Ann Anat Pathol (Paris) 1960, 5:484-497.
62. Mazur MT, Clark HB Gastric stromal tumors: Reappraisal of histogenesis. Am J Surg Pathol 1983, 7(6):507-519.
63. Miettinen M, Monihan JM, Sarlomo-Rikala M, et al. Gastrointestinal stromal tumors/smooth muscle tumors (GISTs) primary in the omentum and mesentery: Clinicopathologic and immunohistochemical study of 26 cases. Am J Surg Pathol 1999, 23(9):1109-1118.
64. Pauls K, Merkelbach-Bruse S, Thal D, et al. PDGFRα- and c-Kit-mutated gastrointestinal stromal tumours (GISTs) are characterized by distinctive histological and immunohistochemical features. Histopathology 2005, 46(2):166-175.
65. Sakurai S, Hasegawa T, Sakuma Y, et al. Myxoid epithelioid gastrointestinal stromal tumor (GIST) with mast cell infiltrations: A subtype of GIST with mutations of platelet-derived growth factor receptorα gene. Hum Pathol 2004, 35(10):1223-1230.
66. Sircar K, Hewlett BR, Huizinga JD, et al. Interstitial cells of Cajal as precursors of gastrointestinal stromal tumors. Am J Surg Pathol 1999, 23(4):377-389.
67. Stout AP Bizarre smooth muscle tumors of the stomach. Cancer 1962, 15:400-409.
68. Berx G, Becker KF, Höfler H, van Roy F Mutations of the human E-cadherin (CDH1) gene. Hum Mutat 1998, 12(4):226-237.
69. Brooks-Wilson AR, Kaurah P, Suriano G, et al. Germline E-cadherin mutations in hereditary diffuse gastric cancer: Assessment of 42 new families and review of genetic screening criteria. J Med Genet 2004, 41(7):508-517.
70. Caldas C, Carneiro F, Lynch HT, et al. Familial gastric cancer: Overview and guidelines for management. J Med Genet 1999, 36(12):873-880.
71. Graziano F, Humar B, Guilford P, et al. The role of the E-cadherin gene (CDH1) in diffuse gastric cancer susceptibility: From the laboratory to clinical practice. Ann Oncol 2003, 14(12):1705-1713.
72. Kaurah P, MacMillan A, Boyd N, et al. Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA 2007, 297(21):2360-2372.
73. Oliveira C, Bordin MC, Grehan N, et al. Screening E-cadherin in gastric cancer families reveals germline mutations only in hereditary diffuse gastric cancer kindred. Hum Mutat 2002, 19(5):510-517.
74. Pharoah PD, Guilford P, Caldas C, International Gastric Cancer Linkage Consortium Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology 2001, 121(6):1348-1353.
75. Suriano G, Yew S, Ferreira P, et al. Characterization of a recurrent germline mutation of the E-cadherin gene: Implications for genetic testing and clinical management. Clin Cancer Res 2005, 11(15):5401-5409.
76. Brankley SM, Wang KK, Harwood AR, et al. The development of a fluorescence in situ hybridization assay for the detection of dysplasia and adenocarcinoma in Barrett's esophagus. J Med Diagn 2006, 8(2):260-267.
77. Flejou J-F, Svrcek M Barrett's oesophagus: A pathologist's view. Histopathology 2007, 50:3-14.
78. Keswani RN, Noffsinger A, Waxman I, Bissonnette M Clinical use of p53 in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 2006, 15(7):1243-1249.
79. Koppert LB, Wijnhoven BP, van Dekken H, et al. The molecular biology of esophageal adenocarcinoma. J Surg Oncol 2005, 92:169-190.
80. Fenollar F, Fournier PE, Raoult D, et al. R Quantitative detection of Tropheryma whipplei DNA by real-time PCR. J Clin Microbiol 2002, 40(3):1119-1120.
81. Fenollar F, Fournier PE, Robert C, Raoult D Use of genome selected repeated sequences increases the sensitivity of PCR detection of Tropheryma whipplei. J Clin Microbiol 2004, 42(1):401-403.
82. Fenollar F, Puechal X, Raoult D, et al. Whipple's disease. N Engl J Med 2007, 356(1):55-66.
83. Lepidi H, Fenollar F, Gerolami R, et al. Whipple's disease: Immunospecific and quantitative immunohistochemical study of intestinal biopsy specimens. Hum Pathol 2003, 34(6):589-596.
84. Raoult D, Fenollar F, Birg ML, et al. Culture of T. whipplei from the stool of a patient with Whipple's disease. N Engl J Med 2006, 355(14):1503-1505.
85. Rolain JM, Fenollar F, Raoult D, et al. False-positive PCR detection of Tropheryma whipplei in the saliva of healthy people. BMC Microbiol 2007, 7:48.
86. Cowgill SM, Muscarella P The genetics of pancreatic cancer. Am J Surg 2003, 186(3):279-286.
87. Hilgers W, Rosty C, Hahn SA Molecular pathogenesis of pancreatic cancer. Hematol Oncol Clin North Am 2002, 16(1):17-35. v.
88. Hiyama E, Kodama T, Shinbara K, et al. Telomerase activity is detected in pancreatic cancer but not in benign tumors. Cancer Res 1997, 57(2):326-331.
89. Khalid A, Pal R, Sasatomi E, et al. Use of microsatellite marker loss of heterozygosity in accurate diagnosis of pancreaticobiliary malignancy from brush cytology samples. Gut 2004, 53(12):1860-1865.
90. Khalid A, Finkelstein S, McGrath K, et al. Molecular diagnosis of solid and cystic lesions of the pancreas. Clin Lab Med 2005, 25(1):101-116.
91. Kipp BR, Stadheim L, Halling SA, et al. A comparison of routine cytology and fluorescence in situ hybridization for the detection of malignant bile duct structures. Am J Gastroenterol 2004, 99:1675-1681.
92. Mishra G, Zhao Y, Sweeney J, et al. Determination of qualitative telomerase activity as an adjunct to the diagnosis of pancreatic adenocarcinoma by EUS-guided fine-needle aspiration. Gastrointest Endosc 2006, 63(4):648-654.
93. Moore PS, Beghelli S, Zamboni G, Scarpa A Genetic abnormalities in pancreatic cancer. Mol Cancer 2003, 2:7.
94. Moreno Luna LE, Kipp B, Halling KC, et al. Advanced cytologic techniques for the detection of malignant pancreatobiliary strictures. Gastroenterology 2006, 131:1064-1072.
95. Moskovitz AH, Linford N, Brentnall TA, et al. Chromosomal instability in pancreatic ductal cells from patients with chronic pancreatitis and pancreatic adenocarcinoma. Genes Chromosomes Cancer 2003, 37:201-206.
96. Niedergethmann M, Rexin M, Hildenbrand R, et al. Prognostic implications of routine, immunohistochemical, and molecular staging in resectable pancreatic adenocarcinoma. Am J Surg Pathol 2002, 26(12):1578-1587.
97. Pogue-Geile KL, Chen R, Bronner MP, et al. Palladin mutation causes familial pancreatic cancer and suggests a new cancer mechanism. PLoS Med 2006, 3(12):2216-2228.
98. Sato N, Ueki T, Fukushima N, et al. Aberrant methylation of CpG islands in intraductal papillary mucinous neoplasms of the pancreas. Gastroenterology 2002, 123(1):365-372.
99. Aretz S, Koch A, Uhlhaas S, et al. Should children at risk for familial adenomatous polyposis be screened for hepatoblastoma and children with apparently sporadic hepatoblastoma be screened for APC germline mutations?. Pediatr Blood Cancer 2006, 47(6):811-818.
100. Donovan A, Roy CN, Andrews NC The ins and outs of iron homeostasis. Physiology (Bethesda) 2006, 21:115-123.
101. Luo JH, Ren B, Keryanov S, et al. Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas. Hepatology 2006, 44(4):1012-1024.
102. Pietrangelo A Molecular insights into the pathogenesis of hereditary haemochromatosis. Gut 2006, 55(4):564-568.
103. Swinkels DW, Janssen MC, Bergmans J, Marx JJ Hereditary hemochromatosis: Genetic complexity and new diagnostic approaches. Clin Chem 2006, 52(6):950-968.
104. Tiao GM, Bobey N, Allen S, et al. The current management of hepatoblastoma: A combination of chemotherapy, conventional resection, and liver transplantation. J Pediatr 2005, 146(2):204-211.
105. Villanueva A, Newell P, Chiang DY, et al. Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 2007, 27(1):55-76.
106. Yen AW, Fancher TL, Bowlus CL Revisiting hereditary hemochromatosis: Current concepts and progress. Am J Med 2006, 119(5):391-399.
107. Zucman-Rossi J, Jeannot E, Nhieu JT, et al. Genotype-phenotype correlation in hepatocellular adenoma: New classification and relationship with HCC. Hepatology 2006, 43(3):515-524.
108. Chou JY, Matern D, Mansfield BC, Chen YT, et al. Type I glycogen storage diseases: Disorders of the glucose-6-phosphatase complex. Curr Mol Med 2002, 2(2):121-143.
109. Coleman RA, Winter HS, Wolf B, et al. Glycogen debranching enzyme deficiency: Long-term study of serum enzyme activities and clinical features. J Inherit Metab Dis 1992, 15(6):869-881.
110. Demo E, Frush D, Gottfried M, et al. Glycogen storage disease type III: Hepatocellular carcinoma a long-term complication?. J Hepatol 2007, 46(3):492-498.
111. Ding JH, de Barsy T, Brown BI, et al. Immunoblot analyses of glycogen debranching enzyme in different subtypes of glycogen storage disease type III. J Pediatr 1990, 116(1):95-100.
112. Gogus S, Kocak N, et al. Histologic features of the liver in type Ia glycogen storage disease: Comparative study between different age groups and consecutive biopsies. Pediatr Dev Pathol 2002, 5(3):299-304.
113. McAdams AJ, Hug G, Bove KE Glycogen storage disease, types I to X: Criteria for morphologic diagnosis. Hum Pathol 1974, 5(4):463-487.
114. Moses SW, Parvari R The variable presentations of glycogen storage disease type IV: A review of clinical, enzymatic and molecular studies. Curr Mol Med 2002, 2(2):177-188.
115. Rake JP, ten Berge AM, Visser G, et al. Glycogen storage disease type Ia: Recent experience with mutation analysis, a summary of mutations reported in the literature and a newly developed diagnostic flow chart. Eur J Pediatr 2000, 159(5):322-330.
116. Rake JP, Visser G, Labrune P, et al. Glycogen storage disease type I: Diagnosis, management, clinical course and outcome. Results of the European Study on Glycogen Storage Disease Type I (ESGSD I). Eur J Pediatr 2002, 161(Suppl 1):S20-S34.
117. Shen JJ, Chen YT Molecular characterization of glycogen storage disease type III. Curr Mol Med 2002, 2(2):167-175.
118. Shin YS Glycogen storage disease: Clinical, biochemical, and molecular heterogeneity. Semin Pediatr Neurol 2006, 13(2):115-120.
119. Talente GM, Coleman RA, Alter C, et al. Glycogen storage disease in adults. Ann Intern Med 1994, 120(3):218-226.
120. Wolfsdorf JI, Weinstein DA Glycogen storage diseases. Rev Endocr Metab Disord 2003, 4(1):95-102.